These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9076812)

  • 21. Meropenem.
    Shah D; Narang M
    Indian Pediatr; 2005 May; 42(5):443-50. PubMed ID: 15923690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the susceptibility trends to meropenem in a nationwide collection of clinical isolates in Japan: a longitudinal analysis from 2002 to 2006.
    Ishii Y; Yamaguchi K;
    Diagn Microbiol Infect Dis; 2008 Jul; 61(3):346-50. PubMed ID: 18339507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical pharmacology and indications of meropenem in severe pediatric infection].
    Honorato J; Sádaba B; Díaz M
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():38-44. PubMed ID: 9410068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program: 1997-2004.
    Jones RN; Mendes C; Turner PJ; Masterton R
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):247-56. PubMed ID: 16360548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery.
    Condon RE; Walker AP; Hanna CB; Greenberg RN; Broom A; Pitkin D
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S181-3. PubMed ID: 9126691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001.
    Jones RN
    Diagn Microbiol Infect Dis; 2001 Dec; 41(4):169, 197-8. PubMed ID: 11777654
    [No Abstract]   [Full Text] [Related]  

  • 28. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].
    Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Uehara N; Yasujima M; Kasai T; Suwabe A; Yamahata K; Kaku M; Kanemitsu K; Imafuku Y; Nishiyama K; Murakami M; Yomoda S; Taniguchi N; Yamada T; Nomura F; Watanabe M; Kanno H; Aihara M; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Yamazaki F; Horii T; Maekawa M; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Iinuma Y; Maeda S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kinoshita S; Fujita J; Negayama K; Murase M; Miyamoto H; Kusano N; Mihara E; Itaha H; Ono J; Yoshimura H; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
    Jpn J Antibiot; 2007 Dec; 60(6):344-77. PubMed ID: 18447206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections.
    Wilson SE
    Clin Infect Dis; 1997 Feb; 24 Suppl 2():S197-206. PubMed ID: 9126694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results.
    Turner PJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):185-92. PubMed ID: 17945455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations.
    Bowker KE; Holt HA; Reeves DS; MacGowan AP
    J Antimicrob Chemother; 1996 Dec; 38(6):1055-60. PubMed ID: 9023653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of borneol on the concentration of meropenem in rat brain and blood.
    Xin HL; He XR; Li W; Zhou ZD; Zhang S; Wang GJ
    J Asian Nat Prod Res; 2014; 16(6):648-57. PubMed ID: 24827508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): a global overview.
    Turner PJ
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():9-23. PubMed ID: 11065145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in-vitro activity of meropenem against clinical isolates including Enterobacteriaceae with expanded-spectrum beta-lactamases.
    Chanal C; Sirot D; Chanal M; Cluzel M; Sirot J; Cluzel R
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():133-41. PubMed ID: 2808205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of meropenem as serine carbapenemases evolve in US Medical Centers: monitoring report from the MYSTIC Program (2006).
    Rhomberg PR; Deshpande LM; Kirby JT; Jones RN
    Diagn Microbiol Infect Dis; 2007 Dec; 59(4):425-32. PubMed ID: 17662557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections.
    Mohr JF
    Clin Infect Dis; 2008 Sep; 47 Suppl 1():S41-51. PubMed ID: 18713049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).
    Rhomberg PR; Jones RN; Sader HS; Fritsche TR;
    Diagn Microbiol Infect Dis; 2004 Aug; 49(4):273-81. PubMed ID: 15313533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
    Pfaller MA; Jones RN
    J Antimicrob Chemother; 2000 Sep; 46 Suppl T2():25-37. PubMed ID: 11065146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UTIs and two new antibiotics in the elderly.
    Jones SR; Kimbrough R
    Geriatrics; 1988 Jul; 43(7):49-52, 55-8. PubMed ID: 3290058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility and beta-lactamase production of selected gram-negative bacilli from two Croatian hospitals: MYSTIC study results.
    Bedenic B; Goic-Barisic I; Budimir A; Tonkic M; Mihajkevic LJ; Novak A; Sviben M; Plecko V; Punda-Polic V; Kalenic S
    J Chemother; 2010 Jun; 22(3):147-52. PubMed ID: 20566417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.